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Abstract
Diabetes mellitus is a global challenge with many diverse health sequelae, of which diabetic peripheral neuropathy is one of
the most common. A substantial number of patients with diabetic peripheral neuropathy develop chronic pain, but the
genetic and epigenetic factors that predispose diabetic peripheral neuropathy patients to develop neuropathic pain are
poorly understood. Recent targeted genetic studies have identified mutations in a-subunits of voltage-gated sodium channels
(Navs) in patients with painful diabetic peripheral neuropathy. Mutations in proteins that regulate trafficking or functional
properties of Navs could expand the spectrum of patients with Nav-related peripheral neuropathies. The auxiliary sodium
channel b-subunits (b1–4) have been reported to increase current density, alter inactivation kinetics, and modulate subcel-
lular localization of Nav. Mutations in b-subunits have been associated with several diseases, including epilepsy, cancer, and
diseases of the cardiac conducting system. However, mutations in b-subunits have never been shown previously to con-
tribute to neuropathic pain. We report here a patient with painful diabetic peripheral neuropathy and negative genetic
screening for mutations in SCN9A, SCN10A, and SCN11A—genes encoding sodium channel a-subunit that have been pre-
viously linked to the development of neuropathic pain. Genetic analysis revealed an aspartic acid to asparagine mutation,
D109N, in the b2-subunit. Functional analysis using current-clamp revealed that the b2-D109N rendered dorsal root
ganglion neurons hyperexcitable, especially in response to repetitive stimulation. Underlying the hyperexcitability induced
by the b2-subunit mutation, as evidenced by voltage-clamp analysis, we found a depolarizing shift in the voltage dependence
of Nav1.7 fast inactivation and reduced use-dependent inhibition of the Nav1.7 channel.
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Introduction
Diabetes mellitus (DM) is one of the world’s leading
causes of morbidity and mortality, affecting over 425
million persons globally and costing the health-care
system US$727 billion annually.1 The health sequelae
of DM are vast and encompass microvascular (retinop-
athy, neuropathy, and nephropathy) and macrovascular
(coronary artery disease, peripheral vascular disease,
and stroke) complications. Of these complications, dia-
betic peripheral neuropathy (DPN) is one of the most
common, with a disease prevalence upward of 50% in
patients with long-standing diabetes.2
DPN can be classified as autonomic or somatic, with
many variants therein, of which distal symmetric poly-
neuropathy (DSP) is the most common.3 DSP typically
presents with a “stocking glove” distribution of sensory
loss due to large-fiber involvement, although painful
burning, prickling, and stabbing sensations are also
often present secondary to small-fiber involvement.
While the disease mechanisms underlying DM are
becoming better understood,4 the pathophysiology of
DPN is still poorly characterized. Current theories
center on the role of hyperglycemia in the development
of neuropathy, as hyperglycemia results in a variety of
cellular defects, including enhanced mitochondrial pro-
duction of reactive oxygen species5 and defects in the
Naþ/Kþ pump.6 However, given the vastly different
symptomatology between painful and painless DPN, as
well as the nonconcomitance between the two presenta-
tions, it is currently unknown whether painful and pain-
less DPN represent different disease states and what
factors might predispose a person with DM to develop
one over the other. Consequently, we set out to identify
genes that might predispose a patient to developing
painful DPN.
Previous genetic studies have implicated voltage-
gated sodium channels (Navs) in neuropathic pain syn-
dromes associated with peripheral neuropathies.7
Classically, gain-of-function mutations in SCN9A, the
gene that encodes the Nav1.7 sodium channel isoform,
are known to cause inherited erythromelalgia (IEM),8–12
paroxysmal extreme pain disorder (PEPD),13–15 and
other painful pain disorders including small-fiber neu-
ropathy (SFN),16 whereas loss-of-function mutations in
this gene result in congenital insensitivity to pain.17–19
However, other sodium channel isoforms have more
recently been implicated in neuropathic pain states.20–26
Nav1.6 knockdown ameliorates mechanical allodynia
after spared nerve injury,21 and a gain-of-function
Nav1.6 mutation has been linked to trigeminal neural-
gia.20 Gain-of-function mutations in Nav1.8 were
reported in three patients with painful peripheral neurop-
athies.22 Further evidence has since followed linking
Nav1.8 mutations to SFN.
24,27 Like Nav1.7 and 1.8,
mutations in Nav1.9 have been reported in patients with
painful peripheral neuropathies.23,25,28 Although the con-
tribution of these Navs to painful neuropathies has been
thoroughly investigated, no human data to date have
shown a role of the b-subunits.
The sodium channel b-subunit family consists of four
genes, SCN1B-SCN4B, encoding four distinct proteins,
b1–4, and two splice variants, b1A and b1B.29,30
Voltage-gated sodium channels are heterotrimeric com-
plexes, composed of one large pore-forming a-subunit
and two small nonpore forming b-subunits (b1/b3 and
b2/b4).31 The b-subunits belong to the superfamily of
cell adhesion molecules,32,33 play roles in the trafficking
of Navs
34 and modulation of Nav function,
35 and muta-
tions in their genes have been associated with a number
of diseases, including epilepsy, cancer, and diseases of
the cardiac conducting system.29 Here, we present the
first known case of a b-subunit contributing to the devel-
opment of a painful phenotype in humans.
Materials and methods
Study population
For this study, 230 participants of the Probing the Role
of Sodium Channels in Painful Neuropathies
(PROPANE) study with painful and 317 participants
with painless DPN were recruited at the University of
Manchester (United Kingdom) and the German
Diabetes Center (Du¨sseldorf, Germany) between June
2014 and September 2016. Local Medical Ethical
Committees of both center approved this study.
Written informed consent was obtained prior to partic-
ipation in this study. The following records were collect-
ed: (1) demographic data, age of onset of complaints,
duration of symptoms, altered pain sensation, medical
history and family history, and prior and current neuro-
pathic pain medication; (2) neurological examination
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(muscle strength, pinprick and temperature sensation,
vibration and position sense, and tendon reflexes); (3)
nerve conduction studies (motor nerve conduction veloc-
ity, compound muscle action potential amplitude, distal
latency: peroneal and/or tibial nerve, sensory nerve con-
duction velocity, and sensory nerve action potential:
ulnar, median, and sural nerve); and (4) multiple ques-
tionnaires, including the 11-point Numerical Rating
Scale (NRS) and Visual Analogue Scale to assess pain
intensity (PI)36 and the Neuropathic Pain Scale to eval-
uate 10 qualities of neuropathic pain.37 As previously
described,38 inclusion criteria for the PROPANE study
were age 18 years, type 1 or type 2 diabetes according
to criteria of the American Diabetes Association, and a
diagnosis of sensory, sensorimotor, and/or small-fiber
DPN as possible, probable, or confirmed according to
the Toronto Consensus criteria.39 Exclusion criteria were
other causes of neuropathy (hypothyroidism, renal fail-
ure, vitamin B12 deficiency, monoclonal gammopathy,
alcohol abuse (>5 U/day), malignancies, drugs known to
cause neuropathy) and concomitant diseases that might
interfere with the participant’s ability to fill in question-
naires. Painful neuropathy was diagnosed in patients
with neuropathic pain40 for more than 1 year and
PI-NRS  4 despite analgesic treatment; painless neu-
ropathy was diagnosed in patients with PI-NRS 3 and
no need for treatment.
DNA isolation from peripheral blood
A peripheral blood sample was taken from all patients,
and genomic DNA was extracted from peripheral blood
by using QIAamp DNA Blood Maxi Kit/PuregeneVR
Blood Core Kit (Qiagen, Hilden, Germany) or
NucleoSpin VR 8 Blood Isolation kit (Macherey-Nagel,
Du¨ren, Germany). Quality and concentration of the
DNA were determined by NanoDrop (Thermo
Scientific, Wilmington, DE, USA) and QubitVR 2.0
Fluorometer using the QubitVR dsDNA BR assay kit
(Life technologies, Bleiswijk, The Netherlands).
Isolated DNA was stored with a unique numeric code
in the central DNA bank at Maastricht University
Medical Centre and IRCCS Foundation “Carlo Besta”
Neurological Institute.
Single-molecule molecular inversion
probe-next-generation sequencing
Coding exons and exon-flanking intron sequences
(20bp) of SCN1B-4B, SCN3A, SCN7A-11A were
sequenced by single-molecule molecular inversion
probe-next-generation sequencing (smMIP-NGS).
Three-hundred-twenty-four smMIPs were designed
using a modified version of MIPgen software (http://
shendurelab.github.io/MIPGEN/). The gap fill length
between the extension and ligation arm (region of inter-
est) of the smMIPs was fixed to 220–230nt. Probes were
synthesized by Integrated DNA Technologies (IDT,
Iowa, IA, USA).
Targeted capture with smMIPs was performed
according to standard protocols.41 In brief, after hybrid-
ization, gap filling and ligation circularized DNA mole-
cules were used as template in a polymerase chain
reaction (PCR) with universal primers complementary
to the linker sequence. Sample-specific barcode sequen-
ces and Illumina adaptors were introduced during the
PCR amplification step. Next, samples were pooled
and purified using Ampure XP beads according to man-
ufacturer’s instructions. Pooled samples were sequenced
using an Illumina NextSeq500 system, with 2 150-bp
paired-end reads (Illumina, Inc., San Diego, CA, USA).
Sequenced data were analyzed using an in-house
smMIP-targeted NGS data analysis pipeline. Variants
were included for analysis with >40 coverage and an
alternative variant call of at least 20%.
To identify sequence variations in SCN1B-4B,
SCN3A, SCN7A-11A, patients’ coding and immediate
flanking regions of these genes were compared with refer-
ence sequence GRCh37. Genetic variations detected were
annotated according to the guidelines of the Human
Genome Variation Society (http://www.hgvs.org/mutno
men/). Variants with a possible pathogenic effect were
classified using Alamut Mutation-Interpretation
Software (Interactive-Biosoftware, Rouen, France).
Classification of variants was based on the practice guide-
lines of the Association for Clinical Genetic Science.42
Variants of interest were confirmed by Sanger sequencing.
Here, we report the smMIP-NGS results for SCN2B.
Molecular modeling
Protein data bank (PDB) structure 5FEB (Crystal struc-
ture of the Voltage-gated Sodium Channel b2-subunit
extracellular domain) from Das et al.43 was opened
and edited in PyMol (Schr€odinger, LLC).
Isolation and transfection of DRG neurons
All animal studies and procedures followed a protocol
that was approved by the Veterans Administration
Connecticut Healthcare System Institutional Animal
Care and Use Committee. Dorsal root ganglia (DRGs)
from 0 to 5 day postnatal Sprague-Dawley rats were
harvested and dissociated as described previously with
minor differences.44 In brief, rat pup (P0-5) DRGs were
dissociated with a 20-min incubation in 1.5mg/mL col-
lagenase A (Roche, Indianapolis, IN, USA) and 0.6mM
EDTA, followed by a 20-min incubation in 1.5mg/mL
collagenase D (Roche), 0.6mM EDTA and 30U/mL
papain (Worthington Biochemical, Lakewood, NJ,
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USA). DRGs were then centrifuged and triturated in 0.5
mL of DRG media containing 1.5mg/mL bovine serum
albumin (low endotoxin) and 1.5mg/mL trypsin inhibi-
tor (Sigma, St. Louis, MO, USA). After trituration, neu-
rons were transfected with either human-b2-D109N or
human-b2-wild type (WT) cDNA containing internal
ribosome entry site (IRES)-GFP using a Nucleofector
IIS (Lonza, Basel, Switzerland) and Amaxa Basic
Neuron SCN Nucleofector Kit (VSPI-1003).
Transfection of HEK293 cells
Human embryonic kidney 293 (HEK293) cells stably
expressing wild-type Nav1.7 were transfected with
either human-b2-D109N or human-b2-WT cDNA con-
taining IRES-GFP using a LipoJet transfection kit
(SignaGen Laboratories, Rockville, MD, USA). Stable
cell lines originated within our laboratory and were pro-
duced using G418 (Geneticin) for cells expressing both
the Nav1.7 channel and the antibiotic-resistance gene on
the same plasmid.
Macroscopic current recordings
Macroscopic currents were recorded from DRG neurons
in both current-clamp and voltage-clamp mode and
HEK293 cells in voltage-clamp mode using an EPC-10
amplifier and the PatchMaster program (HEKA
Elektronik, Holliston, MA, USA) at 25C. Patch pipettes
were pulled from borosilicate glass (1.65/1.1, outside
diameter/inside diameter; World Precision Instruments)
using a Sutter Instruments P-97 puller and had a resis-
tance of 0.8–1.5 MX.
For current-clamp recordings, the extracellular solu-
tion contained the following (inmM): 140 NaCl, 3 KCl,
2 MgCl2, 2 CaCl2, 10 HEPES, and 15 dextrose titrated
with NaOH to a pH of 7.3. Patch microelectrodes were
filled with intracellular solution containing the following
(inmM): 140 KCl, 3 Mg-ATP, 0.5 EGTA, 5 HEPES,
and 30 dextrose titrated with NaOH to a pH of 7.3.
On the day of recordings, the extracellular and intracel-
lular solutions were brought to osmolarities of 320 and
310mOsm, respectively, with dextrose. Whole-cell con-
figuration was obtained in voltage-clamp mode before
transitioning to current-clamp mode. Fluorescent small
DRG neurons (<30 mm in diameter) with stable (<10%
variation) resting membrane potentials (RMPs) more
hyperpolarized than 40mV were included in analysis.
Cells with an input resistance lower than 100 MX were
excluded from analysis. Input resistance was determined
by the slope of a linear fit to hyperpolarizing responses
to current steps from 5pA to 40pA in
5pA increments.
Rheobase was defined as the first current injection
step that resulted in action potential firing without
failure and was determined by a series of depolarizing
current injections (200ms) that increased incrementally
by 5pA. Action potentials were defined as rapid
increases in membrane potential to >40mV with a
total amplitude >80mV. Action potential frequency
was determined by quantifying the number of action
potentials that a neuron fired after a 500-ms current
injection. Action potential amplitudes, upstroke slope,
and maximum rising slope were calculated in the
FitMaster program (HEKA Elektronik).
When recording from DRG neurons, voltage-clamp
extracellular solution contained (inmM): 70 NaCl, 70
Choline-Cl, 20 TEA-Cl, 3 KCl, 1 CaCl2, 1 MgCl2, 0.1
CdCl2, 5 CsCl, 1 4-AP, and 10 HEPES (300 nM tetro-
dotoxin (TTX)). When recording from HEK293 cells,
voltage-clamp extracellular solution contained (in mM):
140 NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, and 10 HEPES. We
used a lower NaCl concentration in the bath solution for
recording sodium current in DRG neurons to reduce the
peak current amplitude and reduce the voltage-clamp
errors due to the very large currents (>20nA) that are
recorded in the physiological sodium concentration of
140mM. Patch microelectrodes were filled with intracellu-
lar solution containing the following (inmM): 140 CsF, 10
NaCl, 1.1 EGTA, and 10 HEPES. Both solutions were
titrated to a pH of 7.3 with NaOH and brought to final
osmolarity (320 mOsm for extracellular solution and 310
mOsm for intracellular solution) with dextrose on the day
of recordings. Series resistance prediction and compensa-
tion (70%–90%) were applied to reduce the voltage errors.
The recorded currents were digitized at a rate of 50 kHz
after passing through a low-pass Bessel filter setting of
10kHz. After achieving whole-cell configuration, a 5-min
equilibration period was allowed before starting the
recording. DRG neurons were held at100mV to prevent
the inactivation of Nav1.9.
Fluorescent DRG neurons under 30 mm in diameter
were recorded from in the whole-cell configuration.
Neurons with a peak voltage error greater than 4mV
or leak greater than 200 pA or 10% of the peak current
were excluded.
Use-dependent inhibition at 20Hz stimulation was
determined by holding neurons at 80mV for 2 ms,
followed by a 10 ms step to 20 mv and measuring
the charge transfer through the cell. Use-dependence
curves were generated by plotting the following
Inormalized ¼ Ixsweep
I1stsweep
To measure sodium channel activation, DRG neu-
rons were pulsed to a range of potentials between
120mV and þ40mV, in 5mV increments, for 100ms
after being held at a holding potential of 100mV. Peak
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inward currents were transformed to conductance using
the equation
G ¼ I
Vm  ENað Þ
The conductance at each voltage was normalized to
the maximum conductance and fit with the following
Boltzmann equation to derive the activation curve
G ¼ Gminþ Gmax Gminð Þ
1þ e VmV0:5ð Þ=Kð Þ
Peak current density was calculated as the peak cur-
rent during the activation pulse normalized to the cellu-
lar capacitance.
To assess steady-state fast inactivation, DRG neurons
were prepulsed to a range of voltages between 140mV
and 0mV in 10mV steps for 500ms from a holding
potential of 100mV and then pulsed to a potential of
10mV. Peak inward current was normalized to the
maximum peak inward current and fit with the following
Boltzmann equation to derive the inactivation curve
I ¼ Iminþ1ð Þ
1þ e VmV0:5ð Þ=Kð Þ
To calculate steady-state sodium channel conduc-
tance, the derived conductance–voltage curves were
modulated by the sodium channel availability curves at
each voltage step. Prior to modulation, each curve was
interpolated to 250 points using a cubic spline interpo-
lation method, allowing for comparison of sodium chan-
nel conductance at more voltages than initially sampled.
Quality of interpolation was assessed visually.
Data analysis. Data were analyzed using FitMaster
(HEKA Elektronik), Microsoft Excel, and Igor Pro
8 (WaveMetrics, Lake Oswego, OR, USA). Data are
presented as means standard error. Student’s t test
was used to analyze all continuous data, except for
use-dependence plots, for which analysis of variance
(ANOVA) with repeated measures was used. All
Student’s t tests are two-tailed unless otherwise noted.
Categorical data were analyzed via chi-square test.
Results
Identification of a novel variant in the coding region of
the SCN2B gene
In our cohort of 230 painful and 317 painless DPN
patients, smMIP-NGS of SCN2B revealed two
heterozygous potentially pathogenic variants that were
specific for the pain phenotype: c.319A>C (K107Q) and
c.325G>A (D109N). Variant D109N was identified in
the coding region of the SCN2B gene in a 61-year-old
male with painful DPN, diagnosed at 42 years old with
type 2 diabetes. It was not found in 317 patients with
painless DPN. The D109N variant is rare in the reported
exome and genome data, with an allele frequency of two
in 282878 in heterozygosity and none in homozygosity.45
As both variants K107Q and D109N were found in
patients with painful diabetic neuropathy localize to sim-
ilar regions of the b2-subunit, both variants merit anal-
ysis and we began by characterizing the D109N variant.
The patient has complained of numbness, burning,
and “pins and needles” paresthesia in his extremities
since 55 years of age (Table 1). Diagnostic testing
showed reduced motor and sensory nerve conduction
in his median, ulnar, common peroneal, and sural
nerves. Sensory nerve action potentials were also
decreased in amplitude, and the patient’s DPN was
graded a score of 9 and 7 on the Neuropathy
Symptom Score and Neuropathy Disability Score
Scales, respectively.
Variant D109N substitutes a residue on the outer sur-
face of the b2-subunit, near the face of the cysteine
responsible for the disulfide linkage to the a-subunit,
potentially interacting with and altering the link between
the b2 and a-subunits (Figure 1).43
Human b2 D109N confers hyperexcitability on
DRG neurons
To test whether the identified D109N variant contributes
to enhanced peripheral nerve excitation, DRG neurons
were isolated from rat pups and transfected with either
wild-type human b2 or the b2 D109N variant.
Excitability of DRG neurons was analyzed using
current-clamp recordings with sample representative
traces as shown in Figure 2(a). The total action potential
amplitude (Figure 2(b)) was unchanged between neurons
expressing the wild-type b2-subunit and the D109N var-
iant (113.28 2.48mV and 112.58 2.85mV, respective-
ly, p¼ 0.85). Consequently, we also examined the
maximum rising slope (Figure 2(c)), which corresponds
to a time point roughly halfway through the upstroke of
the action potential and found no significant difference
between wild-type (97.06 10.21) and mutant DRG
neurons (84.71 10.22, p¼ 0.39). We also examined
the slope of the action potential between the threshold
potential and the Vmax to achieve a more holistic view of
the entire action potential rising phase. The initiation of
the action potential rising phase was determined as the
initial time point where the first derivative of membrane
potential with respect to time exceeded 20 mv/ms, as has
been previously reported by Naundorf et al.46 Here, we
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again did not see a significant difference between DRG
neurons expressing the wild-type b2-subunit (50.46
 4.93 mv/ms) and the D109N variant (47.57
 4.62, p¼ 0.67).
DRG neurons expressing the D109N variant b2-sub-
unit also exhibited a similar RMP as DRG neurons with
the wild-type b2-subunit (Figure 2(d)); neurons express-
ing the D109N variant had an average membrane poten-
tial of 53.7 1.7mV (n¼ 21), which was comparable
to the 56.8 1.8mV (n¼ 21) resting membrane voltage
of DRG neurons expressing the wild-type b2-subunit.
We also quantified the excitability of DRG neurons
expressing either b2-subunit via determination of the
current injection necessary to elicit an action potential
(Figure 2(e)). Rheobase was, similarly, unchanged by the
presence of the D109N variant (213.57 45.29 pA in
D109N-expressing neurons vs. 278.23 60.40 pA in
wild-type neurons, p¼ 0.39).
DRG neurons expressing the D109N mutation, how-
ever, showed significantly increased action potential
firing at larger current stimuli (300–500 pA) compared
to neurons expressing the wild-type b2-subunit (Figure 3
(a), (c), and (d)). However, firing was comparable at
lower current injections, and the percentage of multiply
spiking neurons was not significantly different between
wild-type and mutant neurons (Figure 3(b)). Taken
together, these results indicate that hyperexcitability in
neurons expressing the b2 D109N mutation is primarily
due to increased repetitive firing, rather than a decreased
threshold to first spiking.
The b2 D109N mutation reduces use-dependent
charge transfer inhibition to allow for repetitive firing
Use-dependent inhibition of sodium channels has been
previously shown to reduce the sustained repetitive firing
in neurons.47 To assess whether the b2 mutation results
in reduced use-dependent inhibition, DRG neurons were
voltage-clamped at a hyperpolarizing potential and
depolarized at 20 Hz frequency; charge transfer was
measured at each depolarization and normalized to the
total current passed at the first stimulus. DRG neurons
expressing the mutant b2-subunit exhibited significantly
reduced use-dependent inhibition compared to wild-type
neurons (Figure 4(a)). Neurons expressing the b2 D109N
variant allowed 67.9% of total charge transfer after 1.5 s
of 20 Hz stimulation, which was significantly more than
the 59.1% allowed by neurons expressing the wild-type
b2-subunit (significant by Bonferroni and Tukey
ANOVA with repeated measures).
The mutant b2-subunit does not induce DRG neuron
hyperexcitability through modulation of TTX-resistant
sodium channels
Sodium channel b-subunits interact with all sodium
channels a-subunits. To determine, within intact neu-
rons, which sodium channels are modulated by the
mutant b2-subunit, we conducted the same use-
dependence protocol as illustrated above and measured
the charge transfer before and after application of 300
nM TTX. Post-TTX application, there was no signifi-
cant difference in the use-dependent inhibition of the
TTX-resistant current in neurons expressing the b2
Table 1. Clinical characteristics of a patient with identified DPN
and b2 D109N mutation.
Demographic and clinical data
Age (years) 61
Sex Male
BMI (kg/m2) 34.1
Smoking (pack years) 40
HbA1ca (%) 6.0
HbA1c (mmol/mol) 42
Diabetes mellitus Type 2
Diabetes duration (years) 19
DPN duration (years) 8
Neuropathic pain medication Pregabalin 300 mg daily
Neurological tests Result Evaluationb
Peroneal MNCV (m/s) 33 Abnormal
Median SNCV (m/s) 32 Abnormal
Ulnar SNCV (m/s) 33 Abnormal
Sural SNCV (m/s) 29 Abnormal
Median SNAP (mV) 5.3 Normal
Ulnar SNAP (mV) 6.5 Normal
Sural SNAP (mV) 4.3 Normal
VPT metacarpal (mm) 1.7 Abnormal
VPT malleolar (mm) 4.9 Abnormal
CDT hand (C) 30.1 Normal
WPT hand (C) 33.9 Normal
CDT foot (C) 19.8 Normal
WDT foot (C) 46.7 Abnormal
NSS (points) 9 Abnormal
NDS (points) 7 Abnormal
24 h average NRS
pain score (points)
5 (7c) Abnormal
aHbA1c is a measure of glycated hemoglobin and the most commonly used
method of evaluating glycemic control in patients with diabetes. Per the
American Diabetes Association, one criterion sufficient for diagnosis of
diabetes mellitus is HbA1c  6.5%, although patients are still considered to
have diabetes if HbA1c falls <6.5% with medical treatment.
bEvaluation based on 5th/95th percentiles of the individual reference range;
2.5th/97.5th percentiles were used for NCVs and SNAPs.
cFrom medical history prior to analgesic treatment.
Note: BMI: body mass index; DPN: diabetic polyneuropathy; MNCV:
motor nerve conduction velocity; SNCV: sensory nerve conduction
velocity; SNAP: sensory nerve action potential; VPT: vibration perception
threshold; CDT: cold detection threshold; WDT: warmth detection
threshold; NSS: Neuropathy Symptom Score; NDS: Neuropathy Disability
Score; NRS: Numerical Rating Scale; HbA1c: hemoglobin A1c; WPT: warm
perception threshold.
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Figure 1. Structure of the b2-subunit extracellular domain illustrates the location of the D109N mutation with respect to 55Cys. (a)
PyMol model of the human b2-subunit with the D109 residue (red) shown near the C55 residue (cyan) responsible for disulfide bridge
formation to the Nav1.2 channel. (b) Surface maps illustrate a common surface between the D109 residue (red) and the C55 resi-
due (cyan).
Figure 2. The b2 D109N variant does not alter passive membrane properties or action potential characteristics of DRG neurons. (a)
Sample action potential waveforms representative of collected current-clamp recordings from either wild-type (n¼ 17) or D109N
expressing DRG neurons (n¼ 21). (b) Comparison of total action potential amplitude for DRG neurons expressing either wild-type
(113.28 2.48 mV) or D109N variant (112.58 2.85 mV, p¼ 0.85) b2-subunits. (c) Comparison of maximum slope during rising phase of
action potential between DRG neurons expressing either wild-type (97.06 10.21 mV/ms) or D109N variant (84.71 10.22, p¼ 0.39).
(d) Comparison of resting membrane potential of DRG neurons overexpressing either wild-type (56.8 1.8 mV) or D109N variant
(53.7 1.7 mV, p¼ 0.12) subunit. (e) Comparison of current injection threshold for action potential spiking between DRG neurons
expressing either wild-type (278.23 60.40 pA) or D109N variant (213.57 45.29 pA, p¼ 0.39) b2-subunit.
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D109N mutation when compared against neurons
expressing the wild-type b2-subunit (Figure 4(b)).
Neurons expressing the b2 D109N variant allowed
82.9% of total charge transfer after 1 s of 20 Hz stimu-
lation, which was not statistically different than the
78.3% allowed by neurons expressing the wild-type
b2-subunit.
We also examined the change in current density as a
function of the b2-subunit. As expected, there was no
significant change in TTX-R current density between
DRG neurons expressing the wild-type b2-subunit and
those expressing the D109N variant; D109N-expressing
DRG neurons exhibited a current density of
474.4 149.2 pA/pF (n¼ 7), compared to 397.7 85.9
pA/pF (n¼ 8) in wild-type-expressing DRG neurons
(p¼ 0.65, data not shown). Interestingly, there was
also no change in total current density between neurons
expressing the wild-type (970.9 50.9, n¼ 8) and
D109N variant (975.5 68.3, n¼ 12, p¼ 0.99)
b2-subunit.
The b2 D109N variant depolarizes the voltage
dependence of fast inactivation of total sodium
current in DRG neurons
Classically, mutations in voltage-gated sodium channels
found in peripheral neurons have been implicated in
IEM, PEPD, and SFN. Mutations in Nav1.7 that
result in IEM tend to hyperpolarize the voltage depen-
dence of channel activation,9–12 whereas mutations that
result in PEPD tend to depolarize the voltage depen-
dence of sodium channel fast inactivation.14,15,48
Mutations in Nav1.7, Nav1.8, and Nav1.9 resulting in
SFN often result in a spectrum of changes in channel
gating.16,22–24,49,50 Consequently, we examined whether
the D109N variant in the b2-subunit altered properties
of activation or fast inactivation of sodium channels in
small DRG neurons. The b2 D109N variant results in no
discernible change in the V1/2 of activation (Figure 4(c))
for total sodium current in small DRG neurons (20.14
 3.56mV for neurons expressing the wild-type
Figure 3. b2 D109N confers hyperexcitability to DRG neurons. (a) Comparison of repetitive action potential firing between DRG
neurons expressing wild-type (n¼ 17) and D109N (n¼ 21) b2-subunits across a range of 500 ms current injections from 25 to 500 pA.
Overexpression of b2-subunits with the D109N mutation permits continuous spiking of rat DRG neurons even in the presence of high-
current stimuli, whereas DRG expressing wild-type b2-subunits adapt and cease firing. (b) The D109N mutation in the b2-subunit does
not increase the proportion of cells that fire repetitively. Approximately 52% of neurons recorded in either condition fired multiple action
potentials. (c and d) Sample traces at approximately threshold, 5 threshold, and 10 threshold for DRG cells expressing wild-type b2 (c,
black) and mutant b2-subunits (d, red).
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b2-subunit vs. 17.53 4.31mV for neurons expressing
the b2 D109N variant). However, the V1/2 of fast inac-
tivation (Figure 4(d)) was significantly more depolarized
by 10mV in small DRG neurons expressing the b2
D109N variant (67.81 1.97mV) than the wild-type
b2-subunit (77.44 2.71mV, p¼ 0.015).
The b2 D109N variant modulates Nav1.7 function,
reducing use-dependent inhibition, and depolarizing
the channel’s voltage dependence of fast inactivation
Given that there was no change in TTX-R channel use
dependence, the fast-inactivation curves were well fitted
using a single Boltzmann function and the voltage
dependence of inactivation was close to the expected
value for Nav1.7, and given that Nav1.7 accounts for
roughly 70% of TTX-S current in small DRG neurons,51
we next examined whether the b2 D109N modulated
gating properties of Nav1.7. As HEK293 cells do not
express appreciable levels of endogenous sodium cur-
rents (typically< 200 pA), stable cell lines expressing
only Nav1.7 were transfected with either the wild-type
b2-subunit or the b2 D109N mutant. HEK293 cells
expressing b2 D109N exhibited a rightward shift in the
voltage dependence of fast inactivation when compared
to cells expressing wild-type b2, similar to what was
observed in DRG neurons (Figure 5(a)). The V1/2 of
fast inactivation for Nav1.7 in the presence of b2
D109N was 75.95mV, approximately 6.93mV more
depolarized than Nav1.7 in the presence of wild-type
b2 (V1/2¼82.87, p¼ 0.043). Given also that a reduc-
tion in use-dependent inhibition of TTX-S channels was
observed in DRG neurons, we investigated whether the
b2 D109N mutant also directly affected the channel use-
dependence properties of Nav1.7 (Figure 5(b)). The
presence of the b2 D109N-subunit resulted in reduced
Nav1.7 use-dependent inhibition after 1.5 s of 20 Hz
stimulation (85% current remaining vs. 76%, statistical-
ly significant by two-way ANOVA with repeat-
ed measures).
Discussion
DPN is a chronic complication of DM that affects all
aspects of patients’ lives, with DPN being painful in only
a subset of patients.52 Painful variants of DPN are cur-
rently poorly managed by typical analgesics.53
Consequently, there is a need for both better under-
standing of factors that predispose one to painful neu-
ropathy and therapy targeted to the mechanism
Figure 4. Voltage-clamp analysis of D109N variant. (a) Comparison of use-dependent inhibition of total sodium current after 20Hz
stimulation in DRG neurons expressing either wild-type (I/Imax at 1.5 s¼ 59.1%, n¼ 12) or D109N (I/Imax at 1.5 s¼ 67.9%, n¼ 14)
b2-subunit. (b) Comparison of use-dependent inhibition of TTX-R sodium channels in DRG neurons expressing either wild-type (n¼ 8) or
D109N variant (n¼ 9) showing no difference at 20Hz stimulation. (c) Comparison of voltage dependence of activation in wild type (20.1
 3.6mV, n¼ 9) and D109N (17.5 4.3mV, n¼ 9, p¼ 0.65). (d) Comparison of voltage dependence of fast inactivation in DRG neurons
expressing either wild-type (77.4 2.7mV, n¼ 8) or D109N variant (67.8 2.0mV, n¼ 7).
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underlying the painful DPN. Only recently have studies
attempted to link painful DPN to specific predisposing
mutations. Blesneac et al. discovered 12 rare (<1% prev-
alence) Nav1.7 variants in a cohort of patients with pain-
ful diabetic neuropathy that were not seen in patients
with painless DPN.54 Six of these variants had been pre-
viously described in other neuropathies, such as SFN,
with five resulting in gain-of-function changes in
Nav1.7. Blesneac et al. characterized two of the six pre-
viously uncharacterized Nav1.7 variants found in painful
diabetic neuropathy patients and illustrated gain-of-
function changes in the channels. Here, we report the
first b-subunit mutation to contribute to the develop-
ment of neuropathic pain and DPN.
Previous studies have implicated the b2-subunit in
neuropathic pain; expression of the b2-subunit is upre-
gulated in neuropathic pain following spared nerve
injury, and knockout of the b2-subunit attenuates
mechanical allodynia induced by nerve injury.55 This
injury-induced upregulation of the b2-subunit directly
increases sodium conductance in response to nerve
injury.56 b2-null mice are also known to show reduced
responses to mechanically and inflammatory painful
stimuli. Thus, it follows that, like upregulation, a gain-
of-function mutation in the b2-subunit could also result
in neuropathic pain.
Our results show that the D109N variant in the
b2-subunit enhances hyperexcitability in DRG neurons
via a mechanism that enhances repetitive firing but does
not reduce rheobase (Figures 2 and 3). It is interesting to
note that the RMP of DRG neurons expressing the
D109N variant (53.7 1.7mV) is not different from
the RMP of DRG neurons expressing wild-type b2
(56.8 1.8mV), and, similarly, current threshold for
action potential firing was not altered. Previous work
using dynamic-clamp analysis of Nav1.7 has shown
that an increase in Nav1.7 conductance of 25% results
in statistically significant reductions in current
threshold.51 The D109N mutation imparts approximate-
ly a 100% increase in total sodium channel conductance
(as isolated Nav1.7 channel conductance was not assayed
in DRG neurons) at RMP. Considering the D109N var-
iant’s strong effect on Nav1.7 and this increase in total
sodium channel conductance, we would have anticipated
to observe a reduction in rheobase. One explanation
might be a possible effect of sodium channel b-subunits
on other ion channels. In addition to modulating sodium
channels, the b-subunits also interact with potassium
channels, having been shown to coprecipitate with
them and increase their current density.57,58 Thus, the
net interactions of the D109N with all of its ion channel
partners precluded a reduction in rheobase.
However, neurons expressing b-subunits with this
mutation continued to fire repetitively in response to
large current injections, whereas neurons expressing the
wild-type b2-subunit would adapt and attenuate their
firing at larger current injections. We investigated the
effect of variant D109N on channel use dependence as
a conduit for enhancing repetitive firing and found that
the b2 D109N variant resulted in reduced use depen-
dence of firing in DRG neurons. This presumably
allows repetitive firing by permitting a higher proportion
of channels to continue to gate, rather than inactivate.
Interestingly, this did not result in an increase in current
density (Figure 4). However, this is not surprising given
the fact that current density is a function of peak current
during an activation pulse, and our primary hyperexcit-
ability phenotype is reduced use-dependent inhibition.
In addition, the expression system utilized involved
overexpressing human b2-subunits in rat DRGs already
expressing their normal b-subunits, potentially limiting
how much current density could be increased.
We intended to next find the specific a-subunit by
which the mutant b2-subunit acted to produce hyperex-
citability. Sodium channel b2-subunits have been previ-
ously shown to regulate the TTX-S channels in DRG
Figure 5. Voltage-clamp analysis of Nav1.7 in the presence of the b2 D109N-subunit. (a) Comparison of voltage dependence of fast
inactivation of Nav1.7 in the presence of the D109N variant (76.0 2.2 mV, n¼ 8) and the wild-type b2 (82.9 2.3 mV, n¼ 9,
p¼ 0.043). (b) The presence of the D109N variant (n¼ 6) results in a 9% reduction in use-dependent inhibition of Nav1.7 compared to
wild-type b2 (n¼ 6) after 1.5 s of 20 Hz stimulation.
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neurons,56 which is consistent with the results of this
present study as we saw no change in the use dependence
of TTX-R sodium channels. In addition to a reduction
in use-dependent inhibition, presumably mediated via
TTX-S Navs, in DRG neurons (which could include
Nav1.3, 1.6, and 1.7), we also elucidated a gain-of-
function change in the voltage dependence of fast inac-
tivation for total sodium current. This is consistent with
previous studies that implicated a role for the b2-subunit
in modulating inactivation but not activation of sodium
channels in neurons; Chen et al. showed that knocking
out the b2-subunit results in a hyperpolarized shift of
10.6mV in the half-inactivation voltage to sodium cur-
rent for hippocampal neurons, consistent with a loss-of-
function attribute of the mutation.59 Here, we report a
gain-of-function mutation that results in a depolarizing
shift in the voltage dependence of fast inactivation of the
total sodium current within DRG neurons by approxi-
mately 9.64mV. This biophysical finding is consistent
with mutations that result in other pain syndromes, spe-
cifically PEPD.15,48 As individual traces recorded were
all well fit with a single Boltzmann and the overall V1/2
of fast inactivation was similar to that of Nav1.7,
60
which is responsible for the majority of the TTX-S cur-
rent in small DRG neurons,51 we then investigated if the
mutant b2-subunit modulated Nav1.7. The D109N
mutation resulted in a 6.93mV shift in the fast inactiva-
tion of Nav1.7 (Figure 5(a)), approximately 72% of the
total 9.64mV shift seen in DRG neurons. This is con-
cordant with the previous finding that Nav1.7 is respon-
sible for approximately 70% of TTX-S current in DRG
neurons.51 What this also implies, however, is that
Nav1.7 may not be the only Nav modulated by the
D109N mutant b2-subunit and other TTX-S channels,
such as Nav1.6, may also play a role—although not as
pronounced as Nav1.7.
While the patient’s painful phenotype is congruent
with DRG hyperexcitability and gain-of-function
changes in use-dependent inhibition and voltage depen-
dence of fast inactivation of Nav1.7, the question of the
mechanism underpinning these changes remains
unknown. Das et al. elucidated the crystal structure of
the b2-subunit to 1.35 A˚ resolution and discovered that
the cysteine at residue 55 of the b2-subunit forms a disul-
fide bond with the cysteine at residue 910 in the Domain
II S5–S6 linker of Nav1.2, a neuronal sodium channel
found predominantly in the central nervous system.43
As the D109N mutation shares a surface with the C55
residue on the b2-subunit, it is plausible that it interacts
with the Domain II S5–S6 linker region to exert its gain-
of-function effects on Nav1.7 (and potentially other
TTX-S channels). Indeed, mutations in the Domain II
S5–S6 linker of TTX-S channels have been linked to
different pain syndromes—both increased and
decreased,16,61 highlighting a role for this region in the
development of neuropathic pain.62 In addition, Das
et al. suggest that the b2-subunit may position itself
between either the voltage sensor domains (VSDs) of
Domains I and II or between VSD I and VSD IV.43
Given the importance of Domain IV in controlling fast
inactivation in sodium channels,63–67 it is possible that
the D109N variant also exerts some effect on this locus.
It has also recently been shown that human b-subunits
directly modulate individual VSDs, providing compel-
ling evidence for direct interactions with VSDs.68 Of
note, the inactivated structure of human Nav1.7 in com-
plex with the b1 and b2 structures was recently solved.69
Although a source of vast and important information
regarding Nav1.7 structure, we avoid drawing conclu-
sions on interactions between the a-subunit and the
b-subunits from this structure because the b-subunits
were resolved at a low resolution (4–5 A˚) and showed
quite flexible docking, making it difficult to draw con-
clusive information on their location. Further work is
needed to evaluate whether other mutations in the
b2-subunit (as well as other b-subunits) result in pain
syndromes and, if so, through what mechanisms and
which specific a-subunits. Here, we show that the
D109N variant in the b2-subunit exerts an effect on
fast inactivation and use-dependent inhibition in
Nav1.7, but there may be other mechanisms associated
with other b-subunit mutations.
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